Fadil TA, Khalaf BH, Hussein KI, Hussain SA.Effects of glibenclamide, metformin or their combination on the correlation between serum leptin levels with glycemic control and insulin levels in type 2 DM. J Pharm Biomed Sci. 2011;1(2):23–28.
Abstract
Type 2 diabetes affects millions of people throughout the world. Among the various factors implicated in the causation of this disease, the role of leptin, an obesity gene product, is increasingly being investigated. This study was designed to investigate the relationship between leptin and insulin levels, insulin resistance and glycemic control in newly diagnosed males with type 2 diabetes before and after treatment with either glibenclamide, metformin or their combination. 60 type 2 diabetic patients were recruited for the study and were allocated into 3 groups: one receiving glibenclamide at 5 mg/day, the second receiving 850 mg/day metformin, and the third being treated with a combination of both for 90 days. Blood samples were withdrawn from each patient at zero time and after 90 days for evaluation of HbA1c and plasma levels of glucose, leptin and insulin. The results demonstrated that although all the treatment approaches significantly improved glycemic control, the use of metformin only affected the correlation between plasma leptin levels and insulin and glycemic control. In conclusion, plasma leptin levels vary in type 2 DM patients beyond the state of adiposity and can be used as an indicator for the choice of treatment pattern in those patients.
Customer Reviews
Thanks for submitting your comment!